相关实验视频
Updated: May 24, 2025

09:29
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
Published on: January 9, 2015
15.4K
在帕金森病中患有冲动控制障碍的患者中,血清能功能障碍
Stéphane Prange1,2,3, Elise Metereau1,2, Hélène Klinger2
1Univ Lyon, Lyon Neuroscience Research Center (CRNL), CNRS UMR 5292, INSERM U1028, F- 69675 Bron, France.
Brain : a journal of neurology
|March 5, 2025
概括
帕金森病中的冲动控制障碍与血清系统功能障碍有关,特别是影响参与行为抑制的脑电路. 这项研究突出了多巴胺以外的血清激素异常,有助于理解和管理这些令人痛苦的症状.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 放射学 放射学是一门学科.
背景情况:
- 冲动控制障碍 (ICD) 是帕金森病 (PD) 的常见和令人痛苦的神经精神症状.
- 虽然多巴胺基异常与PD (PDICD+) 中的ICD有关,但血清醇系统在行为抑制中的作用仍然不清楚.
- 了解血清醇功能障碍对于解决PD神经精神病症状至关重要.
研究的目的:
- 为了研究PDICD+患者的前和后突触血清功能障碍.
- 探索皮层-皮层-皮层-皮层电路中所起的作用,涉及抑制控制.
- 在PD中区分血清激素参与行动与决策冲动性.
主要方法:
- 一个前性,病例控制,双指标PET研究.
- 招募了15名PDICD+患者,15名PDICD-患者和15名健康对照,根据年龄和性别进行匹配.
- 使用PET标记物11C-DASB (血清素载体,SERT) 和18F-阿尔坦素 (5-HT2A受体) 来评估血清素内置.
主要成果:
- 患有PDICD+的患者在后骨和骨中表现出更强的11C-DASB结合,这表明在感觉运动网络中保留了前突触SERT可用性.
- 在PDICD+患者的皮质区域 (补充运动区域,中心前环,背侧前额叶皮层) 观察到18F-阿尔坦塞林结合的增加,涉及传感运动和关联网络.
- 在PDICD+患者中,血清突功能障碍特别涉及传感运动和关联性前-上回路,调节行为抑制.
结论:
- 血清能功能障碍有助于帕金森病的冲动控制障碍,特别是在感觉运动和关联性皮质 - 条状 - 状 - thalamic电路内.
- 这些发现超出了边缘电路中已知的多巴胺基异常.
- 血清能系统的变化是导致PD患者患上ICD的脆弱性和发展的关键因素.
相关概念视频
Parkinson's Disease: Treatment
182
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
182
Parkinson's Disease: Overview
419
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
419
Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
202
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
202
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
273
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
273

